Akcea Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Akcea Therapeutics's estimated annual revenue is currently $64.9M per year.(i)
  • 0
  • Akcea Therapeutics's total funding is $751.3M.

Employee Data

Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea () is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence. http://www.fiercebiotech.com/story/isis-launches-cardio-subsidiary-and-recruits-genzyme-vet-run-it/2015-01-07



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Akcea Therapeutics News

09/03/2019 - Akcea Therapeutics And AKCEA-ANGPTL3-LRx: The Story

Liver Therapy Forum weekly digest provides an overview on what's happening in liver diseases in 2019. This week's spotlight is Akcea ...

09/08/2019 - Here's Why Akcea Therapeutics, Inc. (AKCA) Dropped -1.5%

In its most recent trading session, Akcea Therapeutics, Inc. (AKCA) dropped by -1.5% – here is what that looked like (as of 2019-08-23): ...

09/03/2019 - Akcea Therapeutics Inc (NASDAQ:AKCA) Receives Average Rating of “Hold” from Analysts

Akcea Therapeutics Inc (NASDAQ:AKCA) has received an average recommendation of “Hold” from the eight ratings firms that are currently ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding